CD34 and Schnyder corneal dystrophy: In parallel, EDIT-301 is being clinically tested by Editas Medicine, Cambridge, MA, USA, using AsCas12a nuclease to create indels at a BCL11A binding site in the HBG1/2 promoter, with 80% editing (Table 1) in CD34+ cells from patients with SCD, increased HbF production, no off-target editing, and reduced cell sickling (NCT05444894 and NCT04853576).